GFAP and type 2 diabetes mellitus: Despite this limitation, the consistent elevation of GFAP in T2DM-related neurocognitive and vascular conditions lends support to its potential role as an early biomarker of astrocytic dysfunction and warrants future exploration in larger, well-controlled studies.